Email
Print
Male Infertility Market Overview
The Male Infertility Market size was estimated at $3.18 billion in 2020, projected to grow at a CAGR of 4.8% during the forecast period 2021-2026. Male infertility is a condition that is characterized by the failure of a man's reproductive system to achieve a pregnancy after a period of 12 months or more of unprotected sexual activity. Millions of people of reproductive age around the world are affected by infertility, which also has an impact on their families and societies. Infertility affects 48 million couples and 186 million people worldwide, according to WHO estimates. Infertility in men is most often caused by problems with sperm ejection, sperm absence or low amounts, or sperm that have abnormal morphology and movement (motility). Assisted Reproductive Technologies address a broad range of infertility therapies that provide options for males with issues like low sperm count, poor sperm content, and poor motility. Furthermore, as opposed to drugs, Assisted Reproductive Technologies to have a high success rate owing to advances in these technologies as a result the demand for male infertility is expected to expand significantly in the future. Moreover, the increasing acceptance of minimally invasive surgeries will benefit from improved healthcare policies that offer medical coverage and reimbursements to patients all over the world which is also projected to drive the market. However, the lack of trained personnel and high costs associated with treatment is predicted to pose a threat to the market's growth during the forecast period 2021-2026.
Report Coverage
The report: “Male Infertility Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Male Infertility Market.
By Test Type: DNA Fragmentation Technique, Oxidative Stress Analysis, Sperm Agglutination, Computer Assisted Semen Analysis, Sperm Penetration Assay and others.
By Treatment: Assisted Reproductive Technology and Surgery, and Hormone Treatment and Medications.
By Geography: North America (U.S, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Others), Asia-Pacific (China, Japan India, South Korea, Australia and Others), South America(Brazil, Argentina, and others) and Rest of the World (the Middle East and Africa)
Key Takeaways
- Geographically, The Europe region held 31.3% of the total market share in 2020 owing to the availability of well-equipped and specialized fertility clinics and increasing acceptance of expensive treatment options.
- Increase in the prevalence of infertility diseases that demand assisted reproductive technology treatment and surgical procedures is the major driving force for the Male Infertility Market during the forecast period 2021-2026.
- Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Male Infertility Market.
Male Infertility Market Segment Analysis- By Test Type
Based on test type the market is divided into DNA Fragmentation Technique, Oxidative Stress Analysis, Sperm Agglutination, Computer Assisted Semen Analysis, Sperm Penetration Assay, and others test types. Since diagnostic techniques can provide a reliable examination of sperm DNA integrity, DNA fragmentation accounted for the largest market share in 2020. DNA fragmentation is a relatively new technique that has quickly gained popularity and is now widely used in developing countries. Even so, owing to the high cost, the method has yet to gain acceptance in developed countries or be accepted as a normal practice.
However other test types are predicted to grow at a higher CAGR. For instance, Computer-assisted semen analysis is set to expand at a higher CAGR 0f 5.4% during the forecast period owing to technological advances. The most common test for diagnosis is sperm analysis, which can be done using microscopic inspection techniques is also expected to grow significantly.
Male Infertility Market Segment Analysis - By Treatment
Based on treatment, the global market is segmented into assisted reproductive technology and surgery, and hormone treatment and medications. Assisted reproductive technology and surgery account for the highest market share in 2020 and is projected to grow at a CAGR of 5.7% during the forecast period 2021-2026. The dominance in this technology and procedures address a broad range of infertility therapies that provide options for males with issues like low sperm count, poor sperm content, and poor motility. Furthermore, as opposed to hormone treatment and medications, ARTs have a high success rate owing to technological advances thereby the demand for male infertility is expected to expand significantly in the future.
Male Infertility Market Segment Analysis - By Geography
Based on geography, Europe dominated the Male Infertility Market with a regional share of 31.3% in 2020 followed by North America and APAC. The rising geriatric population, diseases, and increasing acceptance of minimally invasive procedures are the major factors driving the growth in this region. Moreover, the presence of a large number of advance and well-equipped specialized fertility clinics and manufacturing companies that invest heavily in R&D is further predicted to propel the market growth in this region. However, the Asia Pacific region is predicted to see the demand maturing in Male Infertility Market owing to the growing population, increased awareness about male infertility disease, and available treatment options during the forecast period 2021-2026.
Male Infertility Market Driver
Increasing incidence of Disease
The global Male Infertility Market is being driven by an increased incidence and prevalence of male infertility diseases. Infertility affects about 8% to 12% of couples around the world. Male factor infertility accounts for about 40 percent to 50 percent in all cases. This may be due to factors including irregular morphology, low sperm concentration, and slow sperm motility, to name a few. Male infertility can also be caused by a number of other factors, including alcohol consumption, smoking, obesity, stress, and lifestyle changes. Moreover growing awareness and continuous advances in the medical device industry to treat Male Infertility are also expected to contribute to market growth during the forecast period.
Male Infertility Market Challenge
High Cost of the Procedure
Although Assisted Reproduction Technologies have been available for more than three decades, and more than 5 million children have been born worldwide as a result of ART interventions such as in vitro fertilization (IVF), they are still largely unavailable, inaccessible, and unaffordable in many parts of the world, particularly in low and middle-income countries which is limiting the adoption procedures. Moreover, the rising stringency in the government regulation also poses a major threat thereby, acting as a major impediment to market growth.
Male Infertility Market Landscape:
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Male Infertility Market. Key companies of this market are Halotech DNA, Bayer AG, EMD Serono Inc., Endo International plc, Vitrolife, Theramex, Aytu BioScience, Sandstone Diagnostics, Inc., Cadila Healthcare Ltd., and CinnaGen Co.
Developments:
- In May 2019, the National Good Laboratory Practice (GLP) Compliance Monitoring Authority (NGCMA), The government of India, awarded the GLP Certification to Cadila Pharmaceuticals for its facility in Dholka.
Relevant reports
Report
Code: HCR 0079
Report Code: HCR 41693
For more Lifesciences and Healthcare related reports, please click here
1. Male Infertility Market Overview
1.1 Definitions and Scope
2. Male Infertility Market Executive Summary
2.1 Market Revenue, Market Size and Key Trends
2.2 Key trends By Test Type
2.3 Key trends By Treatment
2.4 Key trends By Geography
3. Male Infertility Market Landscape
3.1 Product Benchmarking- Key Companies
3.2 Financial Analysis- Key Companies
3.3 Patent Analysis
3.4 Pricing Analysis–Average Pricing
4. Male Infertility Market- Startup companies Scenario Premium Premium Premium
4.1 Key startup company Analysis by
4.1.1 Investment
4.1.2 Revenue
4.1.3 Application Analysis
4.1.4 Venture Capital and Funding Scenario
5. Male Infertility Market- Industry Market Entry Scenario Premium Premium Premium
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case Studies of successful ventures
6. Male Infertility Market Forces
6.1 Market Drivers
6.2 Market Constraints and Challenges
6.3 Porters Five Force Model
6.3.1 Bargaining Power of Suppliers
6.3.2 Bargaining Powers of Customers
6.3.3 Threat of New Entrants
6.3.4 Rivalry Among Existing Players
6.3.5 Threat of Substitutes
7. Male Infertility Market Strategic Analysis
7.1 Value Chain Analysis
7.2 Opportunities Analysis
7.3 Market Life Cycle
8. Male Infertility Market– By Test Type
8.1 DNA Fragmentation Technique
8.2 Oxidative Stress Analysis
8.3 Sperm Agglutination
8.4 Computer Assisted Semen Analysis
8.5 Sperm Penetration Assay
8.6 Others
9. Male Infertility Market– By Treatment
9.1 Assisted Reproductive Technology and Surgery
9.2 Hormone Treatment and Medications
10. Male Infertility Market- By Geography
10.1 North America
10.1.1 U.S
10.1.2 Canada
10.1.3 Mexico
10.2 Europe
10.2.1 U.K
10.2.2 Germany
10.2.3 France
10.2.4 Spain
10.2.5 Italy
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Asia Pacific
10.3.1 India
10.3.2 China
10.3.3 Japan
10.3.4 Australia
10.3.5 South Korea
10.3.6 Rest of Asia pacific
10.4 South America
10.4.1 Brazil
10.4.2 Argentina
10.4.3 Rest of South America
10.5 Rest of the World
10.5.1 Middle East
10.5.2 Africa
11. Male Infertility Market Entropy
12. Male Infertility Market- Industry / Segment Competition landscape Premium Premium
12.1 Market Share Analysis
12.1.1 Market Share by Country- Key companies
12.1.2 Market Share by Region- Key companies
12.1.3 Market Share at Global Level- Key companies
12.1.4 Best Practices for Companies
13. Male Infertility Market- Key Company List by Country Premium Premium Premium
14. Male Infertility Market Company Analysis (Company Revenue, Products, M&A, Developments)
14.1 Company 1
14.2 Company 2
14.3 Company 3
14.4 Company 4
14.5 Company 5
14.6 Company 6
14.7 Company 7
14.8 Company 8
14.9 Company 9
14.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.
LIST OF TABLES
LIST OF FIGURES
1.US Male Infertility Market Revenue, 2023-2030 ($M)2.Canada Male Infertility Market Revenue, 2023-2030 ($M)
3.Mexico Male Infertility Market Revenue, 2023-2030 ($M)
4.Brazil Male Infertility Market Revenue, 2023-2030 ($M)
5.Argentina Male Infertility Market Revenue, 2023-2030 ($M)
6.Peru Male Infertility Market Revenue, 2023-2030 ($M)
7.Colombia Male Infertility Market Revenue, 2023-2030 ($M)
8.Chile Male Infertility Market Revenue, 2023-2030 ($M)
9.Rest of South America Male Infertility Market Revenue, 2023-2030 ($M)
10.UK Male Infertility Market Revenue, 2023-2030 ($M)
11.Germany Male Infertility Market Revenue, 2023-2030 ($M)
12.France Male Infertility Market Revenue, 2023-2030 ($M)
13.Italy Male Infertility Market Revenue, 2023-2030 ($M)
14.Spain Male Infertility Market Revenue, 2023-2030 ($M)
15.Rest of Europe Male Infertility Market Revenue, 2023-2030 ($M)
16.China Male Infertility Market Revenue, 2023-2030 ($M)
17.India Male Infertility Market Revenue, 2023-2030 ($M)
18.Japan Male Infertility Market Revenue, 2023-2030 ($M)
19.South Korea Male Infertility Market Revenue, 2023-2030 ($M)
20.South Africa Male Infertility Market Revenue, 2023-2030 ($M)
21.North America Male Infertility By Application
22.South America Male Infertility By Application
23.Europe Male Infertility By Application
24.APAC Male Infertility By Application
25.MENA Male Infertility By Application
26.EMD Sereno, Inc., Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.Endo International plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Sanofi, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.Bayer Group, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.SCSA Diagnostics, Inc., Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.Andrology Solutions, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.Halotech DNA SL, Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.Intas Pharmaceuticals Ltd., Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.Aytu BioScience, Inc., Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.Cadila Healthcare Ltd., Sales /Revenue, 2015-2018 ($Mn/$Bn)